PH12012500963B1 - 2-fluoro-6-methylene carbocyclic nucleosides and methods of treating viral infections - Google Patents
2-fluoro-6-methylene carbocyclic nucleosides and methods of treating viral infectionsInfo
- Publication number
- PH12012500963B1 PH12012500963B1 PH1/2012/500963A PH12012500963A PH12012500963B1 PH 12012500963 B1 PH12012500963 B1 PH 12012500963B1 PH 12012500963 A PH12012500963 A PH 12012500963A PH 12012500963 B1 PH12012500963 B1 PH 12012500963B1
- Authority
- PH
- Philippines
- Prior art keywords
- virus
- fluoro
- viral infections
- methods
- nucleosides
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 241000701022 Cytomegalovirus Species 0.000 abstract 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000037921 secondary disease Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 229960001997 adefovir Drugs 0.000 abstract 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28134209P | 2009-11-16 | 2009-11-16 | |
| PCT/US2010/056808 WO2011060408A2 (en) | 2009-11-16 | 2010-11-16 | 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12012500963A1 PH12012500963A1 (en) | 2018-05-15 |
| PH12012500963B1 true PH12012500963B1 (en) | 2018-08-10 |
Family
ID=43992463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/500963A PH12012500963B1 (en) | 2009-11-16 | 2010-11-16 | 2-fluoro-6-methylene carbocyclic nucleosides and methods of treating viral infections |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8946244B2 (enExample) |
| EP (1) | EP2501709A4 (enExample) |
| JP (1) | JP5779799B2 (enExample) |
| KR (2) | KR101961601B1 (enExample) |
| CN (1) | CN102725302B (enExample) |
| AP (1) | AP2012006310A0 (enExample) |
| AU (1) | AU2010319999B2 (enExample) |
| CA (1) | CA2781054A1 (enExample) |
| EA (1) | EA201270632A1 (enExample) |
| IL (1) | IL219748A0 (enExample) |
| MX (1) | MX2012005601A (enExample) |
| PH (1) | PH12012500963B1 (enExample) |
| WO (1) | WO2011060408A2 (enExample) |
| ZA (1) | ZA201204356B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| US8816074B2 (en) * | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| US9700560B2 (en) | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
| CN102850402B (zh) * | 2011-06-28 | 2016-08-03 | 李勤耕 | 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途 |
| WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| CN102603652A (zh) * | 2011-12-27 | 2012-07-25 | 河南师范大学 | 5-甲酰基嘧啶碳环核苷及制备方法 |
| MD20140094A2 (ro) * | 2012-02-14 | 2015-03-31 | University Of Georgia Research Foundation, Inc. | Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae |
| EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| BR112014029115A8 (pt) | 2012-05-22 | 2018-04-03 | Idenix Pharmaceuticals Inc | Composto, composição farmacêutica, e, uso de um composto ou composição |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CN104936970A (zh) | 2012-10-08 | 2015-09-23 | 埃迪尼克斯医药公司 | 用于hcv感染的2′-氯核苷类似物 |
| CN103804417B (zh) * | 2012-11-13 | 2017-09-19 | 北京美倍他药物研究有限公司 | 抗乙肝病毒药物 |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| CA2898092A1 (en) * | 2013-02-07 | 2014-08-14 | Tobira Therapeutics, Inc. | Lamivudine salts |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| US9334273B1 (en) | 2014-03-05 | 2016-05-10 | University Of Georgia Research Foundation, Inc. | Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) |
| EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| MY190867A (en) | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| CN106466300B (zh) * | 2015-08-12 | 2019-06-21 | 复旦大学 | 一种装载难溶性药物的复合壳聚糖纳米粒制剂及其制备方法和应用 |
| WO2017127461A1 (en) * | 2016-01-18 | 2017-07-27 | Sensor Electronic Technology, Inc. | Semiconductor device with improved light propagation |
| US10987372B2 (en) | 2016-03-11 | 2021-04-27 | Kagoshima University | Anti-hepatoma-virus agent |
| US10533008B2 (en) * | 2016-04-07 | 2020-01-14 | University Of Georgia Research Foundation, Inc. | Synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) and 2′-fluoro-6′-methylene-carbocyclic guanosine (FMCG) |
| US10653678B2 (en) | 2016-04-11 | 2020-05-19 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| WO2018092728A1 (ja) * | 2016-11-16 | 2018-05-24 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
| WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| KR102337922B1 (ko) | 2018-04-19 | 2021-12-09 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| KR20190121956A (ko) | 2018-04-19 | 2019-10-29 | 가천대학교 산학협력단 | 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물 |
| JP7496132B2 (ja) * | 2018-08-31 | 2024-06-06 | 国立大学法人 鹿児島大学 | 核酸アナログ及び抗ｂ型肝炎ウイルス剤 |
| CN109846887B (zh) * | 2019-03-22 | 2022-12-09 | 南京大学 | 2-氨基嘌呤-6（h）硫酮在制备单纯疱疹病毒的抑制剂中的应用 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4396623A (en) * | 1981-08-26 | 1983-08-02 | Southern Research Institute | Carbocyclic analogs of uracil nucleosides as antiviral agents |
| GB8520553D0 (en) * | 1985-08-16 | 1985-09-25 | Glaxo Group Ltd | Chemical compound |
| WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
| CN1268345C (zh) * | 2000-03-29 | 2006-08-09 | 乔治敦大学 | 治疗丁型肝炎病毒感染的核苷化合物 |
| WO2001085971A2 (en) | 2000-05-10 | 2001-11-15 | Phycogen, Inc. | Transgenic plants incorporating_genes of zostera marina |
| HUP0400726A3 (en) * | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| WO2004002422A2 (en) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US8816074B2 (en) * | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
-
2010
- 2010-11-16 MX MX2012005601A patent/MX2012005601A/es not_active Application Discontinuation
- 2010-11-16 CN CN201080062516.9A patent/CN102725302B/zh not_active Expired - Fee Related
- 2010-11-16 AU AU2010319999A patent/AU2010319999B2/en not_active Ceased
- 2010-11-16 CA CA2781054A patent/CA2781054A1/en not_active Abandoned
- 2010-11-16 EA EA201270632A patent/EA201270632A1/ru unknown
- 2010-11-16 WO PCT/US2010/056808 patent/WO2011060408A2/en not_active Ceased
- 2010-11-16 PH PH1/2012/500963A patent/PH12012500963B1/en unknown
- 2010-11-16 AP AP2012006310A patent/AP2012006310A0/xx unknown
- 2010-11-16 JP JP2012539968A patent/JP5779799B2/ja not_active Expired - Fee Related
- 2010-11-16 KR KR1020187002212A patent/KR101961601B1/ko not_active Expired - Fee Related
- 2010-11-16 US US13/510,090 patent/US8946244B2/en active Active
- 2010-11-16 KR KR1020127015444A patent/KR101840479B1/ko not_active Expired - Fee Related
- 2010-11-16 EP EP10830894.1A patent/EP2501709A4/en not_active Withdrawn
-
2012
- 2012-05-13 IL IL219748A patent/IL219748A0/en unknown
- 2012-06-13 ZA ZA2012/04356A patent/ZA201204356B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011060408A3 (en) | 2011-10-13 |
| AU2010319999B2 (en) | 2014-01-16 |
| KR20180014179A (ko) | 2018-02-07 |
| AP2012006310A0 (en) | 2012-06-30 |
| JP2013510904A (ja) | 2013-03-28 |
| ZA201204356B (en) | 2013-02-27 |
| PH12012500963A1 (en) | 2018-05-15 |
| US20130005677A1 (en) | 2013-01-03 |
| KR101840479B1 (ko) | 2018-03-20 |
| WO2011060408A2 (en) | 2011-05-19 |
| JP5779799B2 (ja) | 2015-09-16 |
| CN102725302A (zh) | 2012-10-10 |
| HK1172628A1 (zh) | 2013-04-26 |
| AU2010319999A1 (en) | 2012-06-21 |
| CN102725302B (zh) | 2016-04-06 |
| CA2781054A1 (en) | 2011-05-19 |
| EP2501709A2 (en) | 2012-09-26 |
| MX2012005601A (es) | 2012-08-01 |
| US8946244B2 (en) | 2015-02-03 |
| KR20120092153A (ko) | 2012-08-20 |
| EP2501709A4 (en) | 2013-11-13 |
| KR101961601B1 (ko) | 2019-03-25 |
| IL219748A0 (en) | 2012-07-31 |
| EA201270632A1 (ru) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500963B1 (en) | 2-fluoro-6-methylene carbocyclic nucleosides and methods of treating viral infections | |
| WO2012158552A3 (en) | 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections | |
| Münz | Latency and lytic replication in Epstein–Barr virus-associated oncogenesis | |
| JP2024055867A (ja) | 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物 | |
| Tsao et al. | The role of Epstein–Barr virus in epithelial malignancies | |
| Neves et al. | Epstein–Barr virus strains and variations: Geographic or disease‐specific variants? | |
| MX2015005500A (es) | Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer. | |
| JO2403B1 (en) | Nickeloside derivatives antiviral | |
| WO2010118367A3 (en) | Antiviral pyrimidines | |
| Albanese et al. | Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host | |
| BR0014172A (pt) | Composição | |
| AU6288096A (en) | Biflavanoids and derivatives thereof as antiviral agents | |
| Le‐Trilling et al. | Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses | |
| EP1340750A4 (en) | amide derivatives | |
| MXPA03001027A (es) | Vacunacion contra herpesvirus asociados a celulas huesped. | |
| NZ338108A (en) | Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections using roscovitine and olomoucine | |
| Chang et al. | Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma | |
| WO2002094844A3 (en) | Antiviral nucleosides | |
| Lambert et al. | Viruses and human cancer | |
| Chow | Cancer and viruses | |
| Ocheni et al. | EBV-associated malignancies | |
| Hiraki et al. | Genetics of Epstein-Barr virus infection | |
| Zhang et al. | Immune evasion strategies of the human gamma‐herpesviruses: Implications for viral tumorigenesis | |
| Khrustalev et al. | Percent of highly immunogenic amino acid residues forming B-cell epitopes is higher in homologous proteins encoded by GC-rich genes | |
| Song | This month in APR |